HOME >> BIOLOGY >> NEWS
Targeted Genetics presents advances in systemic gene delivery technology

--Intravenous gene delivery demonstrates efficacy in pre-clinical studies of breast cancer and head and neck cancer--

San Francisco, CA -- April 3, 2000 -- Targeted Genetics Corporation (Nasdaq: TGEN) today presented data on the company's synthetic gene delivery platform at the American Association of Cancer Research 91st Annual Meeting being held in San Francisco. Dr. Pervin Anklesaria, Senior Director of Research at Targeted Genetics, presented data indicating that the company's LPD (Lipid Polycation DNA) gene delivery system is capable of delivering genes systemically when delivered intravenously. Intravenous delivery of tgLPD-E1A, the company's second-generation cancer therapeutic, inhibited tumor growth in animal models of two different human tumors. The data were presented in an abstract titled "Systemic and Local Delivery of E1A-Cationic Lipid Complex Chemosensitizes Breast and Ovarian Cancer Cells In Vivo."

Advances in Systemic Gene Delivery Technology
In a study presented today, the LPD delivery system was used to deliver E1A, a proprietary tumor inhibitor gene, systemically to mice transplanted with human head and neck tumors. tgLPD-E1A was administered weekly beginning six days after tumor cells were transplanted into the animals. These cells express basal levels of HER-2/neu. At 13 weeks, 70 percent of the animals treated with tgLPD-E1A were tumor free, compared to only 10 percent of animals receiving either lipid alone or 5FU, and only 50 percent of animals receiving a lipoplex-E1A control.

"We have now demonstrated that intravenous delivery of tgLPD-E1A is able to inhibit tumor growth in animal models of breast and head and neck cancers," said Dr. Anklesaria. "These data show that the LPD gene delivery system may enable the systemic delivery of therapeutic genes, an important step in the evolution of gene delivery technologies. Significantly, tgLPD-E1A was seven-fold more effective at inhib
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x229
Noonan/Russo Communications
2-Apr-2000


Page: 1 2 3 4

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. Targeted therapy for lung cancer patients shows promise in extending lives
3. Targeted immunotherapy eradicates cancer in mice
4. Targeted radiation to liver tumors spares tissue, improves quality of life
5. Targeted Genetics presents data on arthritis gene therapy
6. Targeted genetics presents promising data from cystic fibrosis clinical trial
7. Targeted Genetics presents clinical data on E1A cancer gene therapy
8. Targeted Genetics presents advances in synthetic gene delivery technologies
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/12/2019)... ... February 12, 2019 , ... Ava, a 115-pound Newfoundland, ... partially tore one of her cruciate ligaments. Just one year later, she suffered ... was able to recover without surgical intervention and resumed her normal activities without any ...
(Date:2/11/2019)... WASHINGTON (PRWEB) , ... February 11, 2019 , ... ... an Allotrope™ Data Model (ADM), completing the phased release of the Allotrope™ Framework ... new capability combines with the previously released Allotrope™ Data Format (ADF) and application ...
(Date:2/2/2019)... ... January 31, 2019 , ... Pharmica Consulting announced it will ... and focusing on all facets of clinical trial planning and management. Pharmica ... management, patient engagement, and more. , “We have attended the SCOPE Summit ...
Breaking Biology News(10 mins):
(Date:1/24/2019)... ... January 22, 2019 , ... Dr. Douglas Stramel of ... Pall Veterinary Platelet Enhancement Therapy System (V-PET™) for nearly three years. A ... Cell Therapy since 2007 and began using V-PET™ 2016. V-PET™ is a ...
(Date:1/20/2019)... ... January 17, 2019 , ... Consumers are directing healthcare ... of physicians. That's changing as many services now exist for patients to order ... market totaled $208 million in 2018, according to Kalorama Information’s new report, ...
(Date:1/15/2019)... ... January 15, 2019 , ... With the U.S. Congress designating January as Cervical Health ... testing service, today announces tips to help reduce the risk of Cervical Cancer. , ... Genital HPV is the #1 most common STD and an STI that almost ...
(Date:1/10/2019)... ... ... VGI Medical was founded in 2007 based on an invention developed by Tov ... VerteLoc, CerLoc, SiJoin and VerteLP. The VerteLoc and CerLoc systems are specifically designed to ... to limit motion of the affected spinal segment. Applying the principles of this success, ...
Breaking Biology Technology:
Cached News: